CAR T-cell Therapy
Bristol-Myers Squibb’s Abecma Becomes First Approved CAR T-Cell Therapy for Multiple Myeloma in Japan
2022-01-24
ASH 2021: Understanding the Crosstalk between Acute Leukemia and Down Syndrome for Designing Better Therapies
2021-12-16
Considering Manufacturing and Commercial Advantages, Poseida Makes Strategic Shift Towards Allogeneic CAR-T Products
2021-11-10
Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?
2021-09-29
China’s InnoCare, Incyte Enter Collaboration And License Deal for Monoclonal Antibody in Greater China
2021-08-18
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115